The Federal Office of Public Health (FOPH) is set to expand the benefits catalog of compulsory basic health insurance (OKP) starting January 2025, leading to increased healthcare costs. New inclusions, such as helmet therapy for children and the permanent coverage of the Mpox vaccination, are expected to significantly raise expenditures, potentially exceeding CHF 1 billion for the vaccine alone. Despite calls for cost-saving measures, the expansion of services continues without eliminating any existing reimbursements, raising concerns over rising health insurance premiums.
UBS has revised its lithium price forecasts upward for 2025 and 2026, anticipating a tighter market despite a declining outlook for global demand. The bank now expects spodumene prices to reach $800 per tonne in 2025 and $850 per tonne in 2026, citing an 18% reduction in supply estimates due to project delays and price drops. A return to market balance is projected by 2027-2028 as supply growth lags behind demand.
15:48 02.12.2024
UBS has raised its spodumene price forecasts for lithium, anticipating a price of $800 per tonne in 2025 and $850 per tonne in 2026. This adjustment comes despite a declining outlook for global lithium demand, as supply growth is expected to lag behind demand, leading to a tighter market by 2027-2028. The bank has reduced its supply estimate for 2025 by approximately 18% due to supply restrictions and project delays.
15:48 02.12.2024
Infrastructure is crucial for economic progress but has historically contributed to climate issues. Sustainable projects can replace fossil fuels, aiding in climate change mitigation while being economically beneficial. Achieving the 2050 net-zero target in Switzerland and Western Europe is technologically feasible, though social and political challenges remain.
15:46 02.12.2024
UBS has maintained a "Buy" rating for Delivery Hero, setting a target price of 56 euros. The analyst noted that the permanent employment of drivers at the Spanish subsidiary Glovo will help halt rising costs, although unresolved issues regarding past misconduct remain pending a decision from labor authorities.
15:32 02.12.2024
Jupiter Life Line Hospitals has been downgraded to 'Hold' by MarketsMOJO, despite showcasing strong financial performance with a ROCE of 1,892.77% and a long-term growth rate of 33.71%. The company reported a PBDIT of Rs 74.99 crore and a market-beating return of 36.95% over the past year, although its stock is considered expensive with a price to book value of 7.8. Investors are advised to maintain their positions while monitoring future developments.
In 2025, sports fans can look forward to events like the UEFA Women's EURO in Switzerland and the Biathlon World Championships. Economically, a potential boom is anticipated in the U.S. with expected interest rate cuts and corporate profit growth, driven by significant investments in artificial intelligence, projected to reach over $1.1 trillion by 2027.
15:24 02.12.2024
Jack Nathan Medical Corp. has successfully sold its Canadian business to WELL Health Technologies for Cdn$5 million, eliminating over Cdn$15 million in debt and streamlining its capital structure by canceling a convertible debenture and restricted share units. The company retains its profitable operations in Mexico, including 155 clinics in Walmart locations. This strategic repositioning aims to enhance financial flexibility and support future growth initiatives.
UBS has maintained a "Neutral" rating for Siemens Healthineers, setting a price target of €53. Analyst Graham Doyle noted the company's strengthened leadership in photon-counting computed tomography (PCCT) with an expanded product pipeline, allowing them to cater to diverse target groups and budgets.
15:14 02.12.2024
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish kroner. Despite the reavailability of the weight loss drug Wegovy, analyst Jo Walton noted a lack of significant demand increase in the US market.
15:13 02.12.2024
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings